iPSC to β-Islet Cell Differentiation Protocol
A 28-day directed differentiation protocol generating functional insulin-secreting β-like cells from human iPSCs. The protocol follows pancreatic developmental biology through five defined stages, transitioning from 2D monolayer culture to 3D suspension aggregates at Stage 4 to promote islet-like cluster organization and functional maturation. Final β-like cells express INS, NKX6.1, PDX1, MAFA, and C-peptide with glucose-stimulated insulin secretion.
28
Days to Maturity
>65%
C-Peptide+ Cells
2D→3D
Stage 4 Transition
5
Protocol Stages
STAGE 1 Definitive Endoderm Induction (Days 0–3)
1
iPSC Preparation
Expand iPSCs to 80% confluency on Matrigel-coated 6-well plates in mTeSR Plus. Confirm pluripotency markers (OCT4+/NANOG+/TRA-1-60+) by ICC or flow. Passage quality: <5% spontaneous differentiation, passage <35. On Day −1: seed at 1.5 × 10⁶ cells per well in mTeSR Plus + 10 µM Y-27632.
mTeSR PlusMatrigelY-27632
⏲ Day −1 to Day 0
2
Definitive Endoderm Induction
Day 0: Replace media with RPMI 1640 + 0.2% FBS + 100 ng/mL Activin A + 3 µM CHIR99021 (WNT agonist for mesendoderm specification). Day 1: RPMI + 0.2% FBS + 100 ng/mL Activin A (remove CHIR). Days 2–3: RPMI + 0.2% FBS + 100 ng/mL Activin A. Feed daily.
RPMI 1640Activin ACHIR99021FBS
⏲ Days 0–3
3
Definitive Endoderm QC
Day 3: Harvest subset for flow cytometry. Stain for SOX17 and FOXA2. Expected: >90% SOX17+/FOXA2+ double-positive. Also assess CXCR4 surface expression (>85%). If <80% SOX17+, troubleshoot Activin A lot, cell density, or iPSC quality.
SOX17FOXA2CXCR4Flow Cytometry
⏲ Day 3 QC
STAGE 2 Primitive Gut Tube (Days 3–7)
4
Gut Tube Specification
Day 3: Switch to DMEM/F12 + 0.5% BSA + 50 ng/mL FGF10 (fibroblast growth factor for gut tube patterning) + 50 ng/mL KGF (keratinocyte growth factor). Feed every other day. By Day 7: cells should exhibit characteristic flat morphology and express HNF4α and HNF1β.
FGF10KGFDMEM/F12BSA
⏲ Days 3–7
5
Stage 2 QC
Day 7: ICC for HNF4α (nuclear, >70% expected) and FOXA2 (maintained). Optional: qPCR panel for HNF4A, HNF1B, SOX17 (downregulating), and CDX2 (should be negative — indicates intestinal diversion).
HNF4αHNF1βICC
⏲ Day 7 QC
STAGE 3 Posterior Foregut / Pancreatic Progenitor (Days 7–12)
6
Pancreatic Specification
Day 7: Switch to DMEM/F12 + 0.5% BSA + 2 µM retinoic acid (RA, critical for pancreatic fate) + 200 ng/mL Noggin (BMP inhibitor) + 0.25 µM SANT-1 (SHH inhibitor) + 500 nM TPB (PKC activator, Stages 7–9 only). Feed daily. By Day 12: >75% PDX1+ pancreatic progenitors expected.
Retinoic AcidNogginSANT-1TPB
⏲ Days 7–12
7
PDX1 Validation
Day 12: ICC for PDX1 (nuclear, >75%). Co-stain with NKX6.1 (emerging, >15%). qPCR: PDX1 upregulated >100-fold vs iPSC. SOX9 (progenitor marker) should be co-expressed. Passage checkpoint: if PDX1 <60%, consider extending Stage 3 by 1–2 days.
PDX1NKX6.1SOX9ICCqPCR
⏲ Day 12 QC
STAGE 4 Pancreatic Endocrine / 2D→3D Transition (Days 12–20)
8
2D to 3D Aggregate Formation
CRITICAL TRANSITION (Day 12): Dissociate 2D monolayer with TrypLE (37°C, 8 min). Resuspend at 1 × 10⁶ cells/mL in cluster medium: MCDB 131 + 1.5% BSA + 10 µM ALK5 inhibitor II + 1 µM T3 (thyroid hormone) + 20 ng/mL Betacellulin + 100 nM γ-secretase inhibitor XX (Notch inhibitor for endocrine commitment). Seed into ultra-low attachment 6-well plates (Corning) or AggreWell 400 plates for uniform cluster size. Incubate on orbital shaker (70 rpm) in humidified incubator.
TrypLEALK5 Inhibitor IIT3Betacellulinγ-Secretase InhibitorUltra-Low Attachment
⏲ Day 12
9
3D Cluster Formation & Monitoring
Days 13–14: Clusters should form within 24–48h. Target size: 100–200 µm diameter. Feed every other day by tilting plate, allowing clusters to settle (2 min), then removing 80% spent media and replacing with fresh. Monitor: round morphology, no excessive aggregation (>500 µm), no central necrosis. If clusters are too large: reduce seeding density. If too small: increase density or use AggreWell.
MCDB 131Orbital Shaker
⏲ Days 13–16
10
Endocrine Commitment
Days 16–20: Continue cluster medium. By Day 20: NKX6.1+ cells >55%, NGN3 transiently expressed (peaks Day 15–16). Chromogranin A (CHGA) marks committed endocrine cells (>40%). Beginning of insulin expression: C-peptide+ cells >25%. Some glucagon+ cells (α-cell precursors) will also emerge (~10–15%).
NKX6.1NGN3CHGAC-Peptide
⏲ Days 16–20 QC
STAGE 5 β-Cell Maturation (Days 20–28)
11
Maturation Medium
Day 20: Switch to maturation medium: MCDB 131 + 1.5% BSA + 1 µM T3 + 10 µM ALK5 inhibitor II + 1 mM N-acetyl cysteine (NAC, antioxidant for β-cell survival) + 10 µM zinc sulfate (ZnSO₄, supports insulin crystallization) + 100 nM GLP-1 receptor agonist (exendin-4, optional for enhanced maturation). Feed every other day. Maintain on orbital shaker (70 rpm).
T3ALK5 Inhibitor IINACZnSO₄Exendin-4
⏲ Days 20–28
12
Functional Validation (GSIS)
Day 28: Perform glucose-stimulated insulin secretion assay. Pre-incubate clusters in Krebs-Ringer buffer + 2.8 mM glucose (1h, 37°C). Sequential challenge: 2.8 mM glucose (basal, 1h) → 16.7 mM glucose (stimulated, 1h) → 30 mM KCl (depolarization, 30 min). Collect supernatants, measure insulin/C-peptide by ELISA. Expected stimulation index (SI): 2.0–3.0.
Krebs-Ringer BufferGlucoseKClInsulin ELISA
⏲ Day 28 Functional
13
Final QC Panel
Day 28: Flow cytometry for C-Peptide/NKX6.1 co-expression (>65% target). ICC: INS+/NKX6.1+ co-localization, PDX1, MAFA (mature β-cell marker). qPCR panel: INS, GCK, MAFA, NKX6.1, PDX1, SLC30A8, ABCC8, KCNJ11. Calcium imaging: Fluo-4 AM oscillations with glucose stimulation. Cryopreserve validated clusters in mFreSR for future use.
Flow CytometryICCqPCRCalcium Imaging
⏲ Day 28–30